| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/31/2008 | WO2008090223A2 Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus |
| 07/31/2008 | WO2008089795A1 Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids, monoclonal antibodies specific to human hepcidin and associated uses therefor |
| 07/31/2008 | WO2008089569A1 Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens |
| 07/31/2008 | WO2008089567A1 Cancerous disease modifying antibodies |
| 07/31/2008 | WO2008089566A1 Cancerous disease modifying antibodies |
| 07/31/2008 | WO2008089565A1 Cancerous disease modifying antibodies |
| 07/31/2008 | WO2008073466A3 Alpha b-crystallin as a therapy for inflammation |
| 07/31/2008 | WO2008072000A3 Use of integrin alpha 10 binding antibody to modulate extracellular matrix ( cartilage) turnover |
| 07/31/2008 | WO2008067651B1 Gender selection with the use of antibodies |
| 07/31/2008 | WO2008067464A9 NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES |
| 07/31/2008 | WO2008067234A3 Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome |
| 07/31/2008 | WO2008067084A3 Methods for reducing phosphate absorption |
| 07/31/2008 | WO2008063639A3 Compositions and methods for preserving cells of the eye |
| 07/31/2008 | WO2008051797A3 Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases |
| 07/31/2008 | WO2008048289A9 Salmonella based oral vaccines for anthrax |
| 07/31/2008 | WO2008039245A3 Assessment of the effects of topical administration of chemodenervating pharmaceuticals |
| 07/31/2008 | WO2008036146A3 Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins |
| 07/31/2008 | WO2008031061A3 Anti-activin a antibodies and uses thereof |
| 07/31/2008 | WO2008027238A3 Induction of immunosuppression by inhibition of atm |
| 07/31/2008 | WO2008025033A3 Use of il-27 antagonists for the manufacture of a medicament for the treatment of aplastic anemia |
| 07/31/2008 | WO2008020322A3 Combination vaccines with 1-hydroxy-2-phenoxyethane preservative |
| 07/31/2008 | WO2008019366A3 Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens |
| 07/31/2008 | WO2008019199A3 FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| 07/31/2008 | WO2008002933A3 Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| 07/31/2008 | WO2007143104A8 Antibodies as t cell receptor mimics, methods of production and uses thereof |
| 07/31/2008 | WO2007136892A3 Engineered antibody-stress protein fusions |
| 07/31/2008 | WO2007136837A3 Prostate epithelial androgen receptor suppresses prostate growth and tumor invasion |
| 07/31/2008 | WO2007120651A3 Uses and compositions for treatment of juvenile rheumatoid arthritis |
| 07/31/2008 | WO2007101227A3 Identification and use of novopeptides for the treatment of cancer |
| 07/31/2008 | WO2007100640A3 Growth hormone receptor antagonist cancer treatment |
| 07/31/2008 | WO2007085815A8 Ligands that bind il-4 and/or il-13 |
| 07/31/2008 | WO2005019407A3 Polynucleotides, polypeptides and antibodies and use thereof in treating tsg101-associated diseases |
| 07/31/2008 | US20080182976 kit for detecting erythropoietin receptors which is capable of being activated comprising an antibody or fragment which activates formation or production of erythrocytes; treatment of anemia |
| 07/31/2008 | US20080182975 Framework-Patched Immunoglobulins |
| 07/31/2008 | US20080182867 Administering one or more rapamycin derivatives (including rapamycin and 40-O-(2-hydroxy)ethyl-rapamycin); lymphocytic leukemia, lymphoma, Epstein-Barr virus, inhibiting graft rejection and metastasis; drug screening |
| 07/31/2008 | US20080182320 Two-step immunization procedure against chlamydia infection |
| 07/31/2008 | US20080182319 nucleotide sequence encoding a specific binding member or antibody VH or VL domain of a specific binding member that binds human eotaxin chemoattractants (eotaxin) for modulating inflammatory response; antiinflammtory agents; antiallergens; host cell |
| 07/31/2008 | US20080182314 Neuronal serine threonine protein kinase |
| 07/31/2008 | US20080181949 Nanoemulsion Vaccines |
| 07/31/2008 | US20080181918 Immunogens; vaccines; fusion proteins |
| 07/31/2008 | US20080181917 Methods for therapeutic treatment of carpal tunnel syndrome |
| 07/31/2008 | US20080181916 Contains inactive strains of Borrelia genospecies; serums; antibodies |
| 07/31/2008 | US20080181915 Cd40 ligand adjuvant for respiratory syncytial virus |
| 07/31/2008 | US20080181914 an inactivated, disrupted influenza virus preparation of a hemagglutinin antigen stabilised by alpha-tocopherol succinate in the absence or at low levels of thiomersal; hemagglutinin detectable by a single radial immunoassay (SRID); mercury-free preservative; administering by any route |
| 07/31/2008 | US20080181913 Sugar immunogens |
| 07/31/2008 | US20080181912 Nucleotide sequences encoding vector expressing in vivo at least one immunogen of pathogen and an in vivo expression vector comprising a polynucleotide encoding a polypeptide having an insulin-like growth factor IGF-1 activity; immunogenic composition |
| 07/31/2008 | US20080181911 Use Of An Influenza Virus, An Oil-In-Water Emulsion Adjuvant, To Induce Cd4 T-Cell And/Or Improved B-Memory Cell Response |
| 07/31/2008 | US20080181910 administering a porcine circovirus type 2 (PCV2) antigen, such as recombinant baculovirus expressed ORF2 antigen to a pig; lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes |
| 07/31/2008 | US20080181909 Chimeric immunomodulatory compounds and methods of using the same |
| 07/31/2008 | US20080181908 Genes and proteins, and their use |
| 07/31/2008 | US20080181907 Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia |
| 07/31/2008 | US20080181906 For inducing neutralizing antibodies against HIV; hairpin motif; HIV gp120; hydrogen bonding |
| 07/31/2008 | US20080181905 Nanoemulsion Vaccines |
| 07/31/2008 | US20080181904 Contains collagen-like domain and Clq domain; idiotypic antibodies; humanizing; biosynthesis |
| 07/31/2008 | US20080181903 Urodilatin; immunoglobulins; fusion proteins; pharmacokinetics |
| 07/31/2008 | US20080181902 Mutant protofibril for active immunisation; synuclein genes, proteins; Parkinson's disease; dementia |
| 07/31/2008 | US20080181901 Protein modulator of the plasma membrane Na,K-ATPase |
| 07/31/2008 | US20080181900 Vascular Endothelial Cell Growth Factor Antagonists |
| 07/31/2008 | US20080181899 Blocks binding to Notch receptor; surface plasmon resonance |
| 07/31/2008 | US20080181898 Wise/sost nucleic acid sequences and amino acid sequences |
| 07/31/2008 | US20080181897 Which specifically bind to or interact with human G-CSF receptor and dimerize the receptor or activate phosphorylation of kinases associated with the receptor to stimulate cell proliferation and differentiation |
| 07/31/2008 | US20080181896 Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers |
| 07/31/2008 | US20080181895 SP16 protein |
| 07/31/2008 | US20080181894 Tumor/cancer antigens; solid phase synthesis; drug screening |
| 07/31/2008 | US20080181893 Therapeutic methods for treating vascular eye disorders with DII4 antagonists |
| 07/31/2008 | US20080181892 Binding Domain Fusion Protein |
| 07/31/2008 | US20080181891 Modified human igf-ir antibodies |
| 07/31/2008 | US20080181890 antibody or immunoadhesin increases binding affinity to an Fc variants; amino acid substitution; glycosylated Fc; computer aided drug design; drug target |
| 07/31/2008 | US20080181889 antagonist of epithelial membrane protein-2, blocking the entry of Chlamydia into the host cell; biodrug for treating gramnegative bacteria intracellular prokaryotic pathogens; drug screening |
| 07/31/2008 | US20080181888 Polypeptides That Bind Br3 and Uses Thereof |
| 07/31/2008 | US20080181887 fusion protein comprises a non-IgG polypeptide covalently linked to modified with one or more amino acid Immunoglobulins IgG constant domain or a fragment thereof that binds to FcRn ((Fc Receptor-neonate); vaccines; smaller amounts and less frequent dosing |
| 07/31/2008 | US20080181886 Polypeptides That Bind Baff And/Or April |
| 07/31/2008 | US20080181885 202P5A5 gene or fragment or its encoded protein, or variants , or a fragment, used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 202P5A5 be used in active or passive immunization; gene therapy, immunotherapy; anticarcinogenic agent biodrug for pancreatic cancer |
| 07/31/2008 | US20080181884 administering a synergistic mixture comprising an antibody, Anidulafungin (LY303366) and amphotericin B; for drug resistanct infections; induce immunology response; diagnosis of a patient with a Coccidioidomycosis infection |
| 07/31/2008 | US20080181883 Purified Antigen for Alzheimer's Disease and Methods of Obtaining and Using Same |
| 07/31/2008 | US20080181882 treating a neuropsychiatric disorder with siRNA, polyamides, antisense RNA, synthetic peptide nucleic acids, antibody, Fab fragment; enhancing tyrosine phosphorylation; long lasting treatment, inhibit side effects; biodrugs; gene therapy; drug screening |
| 07/31/2008 | US20080181881 drug screening a polypeptide antagonist or antibody that binds to the acid-sensing ion channel 3; antisense nucleic acid that inhibit or decreases the expression level of the acid-sensing ion channel 3; treating glucose intolerance of metabolic disorders |
| 07/31/2008 | US20080181867 preparing a pre-concentrate by emulsifying an oil phase castor oil with water and a water soluble pharmaceutically active substance cyclosporine A, then dilute to desired concentration; eye drops for eye disorders; less time and low energy consuming, no negative impact on the chemical stability |
| 07/31/2008 | US20080181847 kit of imaging probe, e.g.substituted triphenyl phosphine-paramagnetic metal(tetraazacyclododecane) complex; and targeting probe comprises the at least one azide group |
| 07/31/2008 | DE102007004938A1 Medicament for avoiding or alleviating large clostridial cytotoxins, comprises an effector, which is an inhibitor or activator of the protease activity of large clostridial cytotoxins |
| 07/31/2008 | DE102007004909A1 Use of pancreatic zymogen granule polypeptide GP2 as a medicament, especially for treating autoimmune diseases by plasmapheresis |
| 07/31/2008 | CA2696603A1 Jc virus vaccine |
| 07/31/2008 | CA2676611A1 Methods and compositions for depleting specific cell populations from blood tissues |
| 07/31/2008 | CA2676529A1 Genetically recombinant antibody composition having enhanced effector activity |
| 07/31/2008 | CA2676481A1 Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens |
| 07/31/2008 | CA2676244A1 Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| 07/31/2008 | CA2676234A1 Use of antibody conjugates |
| 07/31/2008 | CA2676091A1 Methods and biomarkers for diagnosing and monitoring psychotic disorders |
| 07/31/2008 | CA2676008A1 Compositions and methods for diagnosing and treating cancer |
| 07/31/2008 | CA2675625A1 Chronic rejection inhibitor |
| 07/31/2008 | CA2675521A1 Human cancer stem cells |
| 07/31/2008 | CA2675433A1 Methods and compositions for enhancing growth of fish and shellfish |
| 07/31/2008 | CA2675297A1 Treatment of immune disease by mucosal delivery of antigens |
| 07/31/2008 | CA2675293A1 Cancerous disease modifying antibodies |
| 07/31/2008 | CA2675292A1 Cancerous disease modifying antibodies |
| 07/31/2008 | CA2674897A1 Cancerous disease modifying antibodies |
| 07/31/2008 | CA2674021A1 Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (gp2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis |
| 07/31/2008 | CA2669412A1 Optimized cd40 antibodies and methods of using the same |
| 07/31/2008 | CA2657626A1 Viral inhibitory nucleotide sequences and vaccines |
| 07/30/2008 | EP1950302A2 Streptococcus antigens |